Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2021-04-14 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞独立董事关于第一届董事会第十七次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on various proposals related to the company's first board meeting's 17th session. It discusses approval of fundraising usage reports, profit distribution, remuneration plans, audit firm appointment, related party transactions, credit facilities, accounting policy changes, and authorization for simplified stock issuance. The document references compliance with listing rules and company bylaws, and it is signed by independent directors. It does not contain financial statements or detailed financial data but rather opinions and approvals on board matters and proposals to be submitted to the annual shareholders meeting. This fits the category of Board/Management Information (MANG), as it relates to board meeting decisions and management proposals rather than a full annual report or audit report. The document length is under 5,000 characters, but it is not merely an announcement of a report; it contains substantive board opinions. Therefore, the best classification is MANG with high confidence.
2021-04-14 Chinese
神州细胞关于2021年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's expected related party transactions for the fiscal year 2021. It includes details about the nature, approval process, amounts, and impact of these transactions. The document is relatively short (3305 characters) and focuses on disclosure of anticipated related party dealings rather than presenting financial statements or comprehensive financial performance data. It does not contain actual financial results or detailed financial analysis. The content aligns with regulatory disclosure requirements for related party transactions rather than an annual report, interim report, or audit report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-04-14 Chinese
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司2020年度持续督导跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2020年度持续督导跟踪报告" (2020 Annual Continuous Supervision Follow-up Report) issued by the sponsor (中信证券股份有限公司) for the company 北京神州细胞生物技术集团股份公司. It references regulatory frameworks related to securities issuance and listing supervision, and details the sponsor's ongoing supervision activities, risk factors, financial data, and compliance with regulations. The document contains substantive financial data, risk disclosures, and detailed supervisory activities rather than just an announcement or certification. It is not a full annual report (10-K) but a specific continuous supervision follow-up report required by the stock exchange and securities regulators. This type of document aligns with the category of Audit Report / Information (AR), which includes standalone audit reports, applied accounting principles, and regulatory or internal stress test results excluding full annual reports. The document is too detailed and lengthy to be a simple announcement (RPA) or regulatory filing (RNS), and it is not a management report (MDA) or other categories. Therefore, the best fit is AR (Audit Report / Information). FY 2020
2021-04-14 Chinese
神州细胞董事会审计委员会2020年度履职报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2020年度履职报告" (2020 Annual Performance Report) of the Board Audit Committee of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the audit committee's composition, meetings held during 2020, supervision and evaluation of the external audit firm, internal audit guidance, review of financial reports, assessment of internal controls, and coordination between management and auditors. The content focuses on the audit committee's activities and oversight related to the company's financial reporting and internal controls for the year 2020. It is not a full annual report (10-K), nor is it a standalone audit report (AR) in the strict sense, but rather a report on the audit committee's performance and duties during the year. This type of document aligns with the category of Audit Report / Information (AR), which includes reports on audit committee activities, audit results, and internal control assessments. The document is 2417 characters long, which is relatively short but contains substantive content about audit committee duties and evaluations, not merely an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2020
2021-04-14 Chinese
神州细胞2021年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2021 年第一季度报告" which translates to "2021 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2021. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content includes unaudited financial statements and management commentary on financial results for a period shorter than a full fiscal year, consistent with an interim or quarterly report. There is no indication that this is an annual report, audit report, earnings release, or any other specific filing type. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-04-14 Chinese
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司2021年度日常关联交易预计事项的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion from a sponsoring institution (中信证券股份有限公司) regarding the 2021 annual expected related party transactions of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It includes descriptions of the review process, board and supervisory committee approvals, transaction amounts, related party details, and the sponsor's conclusion on the fairness and necessity of the transactions. The document is not a full financial report but rather an audit or verification opinion on specific related party transactions for the year 2021. It does not contain comprehensive financial statements or quarterly results, nor is it a brief announcement or a presentation. The document fits the definition of an Audit Report / Information (AR) as it provides an audit opinion on related party transactions and compliance with regulatory requirements. FY 2021
2021-04-14 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.